Sitagliptin Tablet, Film Coated
Product Images NDC 84677-051

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sitagliptin (NDC 84677-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

84677-049-30lb.jpg (84677 049 30lb)

Label for Sitagliptin Tablets, USP 25 mg film-coated oral tablets. The package contains 30 tablets and is marked for prescription use only. The label includes dosage and storage instructions, a barcode, and identifies GSMS, Incorporated as the marketer. The NDC number is 84677-049-30.*

FDA Label Image

84677-050-90lb.jpg (84677 050 90lb)

Sitagliptin 50 mg tablets, USP film-coated oral tablets label by Golden State Medical Supply, Inc. The label indicates a 90 tablet bottle with Rx only status. It includes dosage instructions, storage conditions, and manufacturer details from GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

84677-051-30lb.jpg (84677 051 30lb)

Sitagliptin 100 mg film-coated tablets label from Golden State Medical Supply, Inc. The label shows the drug name, strength, and dosage form. It indicates a bottle containing 30 tablets, prescription only. Additional information includes dosage instructions, storage conditions, and manufacturer details, along with a barcode and NDC number 84677-051-30.*

FDA Label Image

Figure1 (Figure1)

A line graph showing the least squares mean change from baseline over 24 weeks for various treatments including placebo, Metformin 500 mg b.i.d. and 1000 mg b.i.d., Sitagliptin 100 mg q.d., and combinations of Sitagliptin 50 mg b.i.d. with Metformin 500 mg b.i.d. or 1000 mg b.i.d. The x-axis represents weeks, and the y-axis shows mean change from baseline.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting the least squares mean change from baseline over 52 weeks for Sitagliptin 100 mg and Glipizide. The x-axis represents weeks, and the y-axis shows change from baseline. Data points for Sitagliptin 100 mg are marked with diamonds and for Glipizide with circles, showing trends of both treatments over time.*

FDA Label Image

Chemical-structure (Sitagliptin 01)

Chemical structure of sitagliptin phosphate monohydrate, depicting the molecular arrangement of its active ingredient in the drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.